Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

Summary

This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle

Timeline

Start

2022-06-23

Primary completion

2025-12-30

Completion

2026-12-31

Outcome

Met primary endpoint

release “Summary of CL-QRX003-004 Interim Results in Netherton Syndrome The primary endpoint of 1-grade improvement or greater for IGA on all of the treatment area met” quoinpharma.com ↗

Drugs

Indications